证券之星消息，8月5日化学原料板块较上一交易日上涨0.8%，中毅达领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。化学原料板块个股涨跌见下表： 从资金流向上来看，当日化学原料板块主力资金净流入3.06亿元，游资资金净流出2797.78万元，散户资 金净流出2.78亿元。化学原料板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600610 | 中毅达 | 3.11 Z | 23.58% | -9750.40万 | -7.40% | -2.13 Z | -16.18% | | 003017 | 大洋生物 | 5003.44万 | 12.79% | -188.92万 | -0.48% | -4814.52万 | -12.31% | | 000818 | 航锦科技 | 4002.27万 | 7.66% | -2631.68万 | -5.04% ...

金融界消息 截至2025年8月5日收盘，大洋生物（003017）报收于33.99元，上涨2.88%，换手率 16.81%，成交量11.65万手，成交金额3.91亿元。 资金流向方面，今日主力资金净流入5003.44万元，占比成交额12.79%。其中，超大单净流入3471.23万 元、占成交额8.87%，大单净流入1532.20万元、占成交额3.92%，中单净流出流出188.92万元、占成交 额0.48%，小单净流出4814.52万元、占成交额12.31%。 大洋生物最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比增长27.78%，归属净利 润2934.32万元，同比增长73.44%，扣非净利润2976.10万元，同比增长88.88%，流动比率1.285、速动比 率1.063、资产负债率34.58%。 天眼查商业履历信息显示，浙江大洋生物科技集团股份有限公司，成立于1976年，位于杭州市，是一家 以从事化学原料和化学制品制造业为主的企业。企业注册资本8400万人民币，实缴资本8400万人民币。 公司法定代表人为陈阳贵。 通过天眼查大数据分析，浙江大洋生物科技集团股份有限公司共对外投资了15 ...

证券之星消息，8月1日化学原料板块较上一交易日上涨0.15%，大洋生物领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。化学原料板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学原料板块主力资金净流出3.0亿元，游资资金净流入2276.85万元，散户资金 净流入2.77亿元。化学原料板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 003017 | 大洋生物 | 33.09 | 5.42% | 11.25万 | 3.73亿 | | 000691 | *ST亚太 | 6.67 | 5.04% | 21.62万 | 1.43亿 | | 000545 | 金浦钦业 | 2.72 | 3.03% | 39.28万 | 1.06亿 | | 603067 | 振华股份 | 14.67 | 2.59% | 25 ...

Group 1 - The recent institutional research by Jianxin Fund focused on the potassium carbonate industry, covering supply and demand, product substitutability, acquisition plans, and market demand for hydrochloric acid aminopropyl [1] - The total national production capacity for potassium carbonate is 290,000 tons, with an expected actual production of approximately 230,000 tons per year in 2024, and a demand growth rate of 5%, which is slightly slowing down [1] - Hydrochloric acid aminopropyl, used as an anti-coccidial drug, has stable demand with increased sales and prices compared to last year due to a rise in customers and multi-channel suppliers [1] Group 2 - Jianxin Fund was established in 2005 and currently manages a total asset scale of 922.483 billion yuan, ranking 11th out of 210 in public fund management [2] - The best-performing public fund product in the past year is Jianxin Flexible Allocation Mixed A, with a latest net value of 1.57 and a growth of 78.7% over the past year [2]

Group 1 - The company, Dayang Bio (003017.SZ), recently stated that there is no public data regarding the production capacity of its competitor, Huibao, in Israel [1] - The company's sales volume of hydrochloride aminophenol has shown a certain growth compared to the same period last year [1] - The current production capacity of hydrochloride aminophenol is 600 tons per year, and it is operating at full capacity [1] - The company has an additional production capacity of 800 tons per year under construction, which is expected to be completed by June next year [1]

Core Viewpoint - The company has significant expertise in fluorochemical production, leveraging over 30 years of experience in the industry, which provides a competitive advantage in the production of PEEK upstream raw material fluorobenzene and intermediate fluoroketone [1] Group 1 - The company possesses production facilities for PEEK upstream raw material fluorobenzene [1] - The company has developed pilot technology for PEEK intermediate fluoroketone [1] - The company's deep understanding of fluorochemistry enhances its technical and industrial advantages [1]

Group 1 - The company, Dayang Bio (003017.SZ), primarily sells hydrochloride aminophenol to regions including the Americas, Africa, Europe, and Southeast Asia [1] - Long-term customers who signed contracts at the beginning of the year continue to fulfill their orders at the contracted prices, while other order prices are adjusted based on market demand [1] - The company has not incurred tariff costs due to tariff issues, and feedback from market demand indicates that tariff policies have a limited impact on the company [1]

（文章来源：每日经济新闻） 2024年1至12月份，大洋生物的营业收入构成为：化工行业占比93.55%，其他占比6.45%。 大洋生物（SZ 003017，收盘价：31.39元）发布公告称，2025年7月29日-30日，大洋生物接受方正证券 等投资者调研，公司董事会秘书徐旭平、证券法务部专员温耀婷参与接待，并回答了投资者提出的问 题。 ...

Group 1: Market Overview - The total production capacity of the potassium carbonate industry in China is 290,000 tons, with an actual production of approximately 230,000 tons in 2024. The overall market demand is growing steadily at a rate of about 5%, although the growth rate is slightly slowing down [2]. - A company in Hubei is implementing a project to co-produce potassium carbonate from potassium hydroxide, which will increase supply capacity. This may impact the sales market in the short term despite some growth in application demand [5]. Group 2: Product Substitution and Pricing - Potassium carbonate is primarily used in food, pharmaceuticals, fertilizers, pesticides, oil and gas, construction materials, electronics, glass, rubber, and steel production. There is a price difference of 700-900 RMB per ton between heavy and light potassium carbonate, which can lead to substitution in high-end applications when the price difference exceeds this range [3]. - The price trend of hydrochloric acid aminopropyl is influenced by market and cost factors, and the company believes the current price fluctuations are within a reasonable range [10]. Group 3: Company Strategy and Development - The company is open to mergers and acquisitions to utilize industry resources for steady growth, adhering to risk control principles [4]. - The company plans to continue its "one body, two wings" development strategy, focusing on potassium salts while expanding into the fluorine industry and increasing its veterinary drug offerings [14]. Group 4: Production Capacity and Market Demand - The current production capacity for hydrochloric acid aminopropyl is 600 tons per year, operating at full capacity, with an additional 800 tons under construction expected to be completed by June next year [7]. - The demand for hydrochloric acid aminopropyl has increased this year, partly due to customers seeking to diversify suppliers amid geopolitical instability affecting a competitor's production [6]. Group 5: Competitive Landscape and Market Position - The company faces competition in the hydrochloric acid aminopropyl market primarily from itself and a competitor in Israel. New entrants face high technical barriers, and their impact on the market remains limited [8]. - The company has strategic investments in semiconductor technology through its stake in Zhejiang Xinzhichun Semiconductor Company, aiming to tap into high-tech sectors encouraged by national policies [19].

天眼查商业履历信息显示，浙江大洋生物科技集团股份有限公司，成立于1976年，位于杭州市，是一家 以从事化学原料和化学制品制造业为主的企业。企业注册资本8400万人民币，实缴资本8400万人民币。 公司法定代表人为陈阳贵。 通过天眼查大数据分析，浙江大洋生物科技集团股份有限公司共对外投资了15家企业，参与招投标项目 59次，知识产权方面有商标信息15条，专利信息111条，此外企业还拥有行政许可89个。 来源：金融界 金融界消息 截至2025年7月30日收盘，大洋生物（003017）报收于32.17元，上涨6.88%，换手率 19.58%，成交量13.56万手，成交金额4.23亿元。 资金流向方面，今日主力资金净流入2582.64万元，占比成交额6.11%。其中，超大单净流入2261.76万 元、占成交额5.35%，大单净流入320.88万元、占成交额0.76%，中单净流出流入187.28万元、占成交额 0.44%，小单净流出2769.92万元、占成交额6.55%。 大洋生物最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比增长27.78%，归属净利 润2934.32万元，同比增长73.44% ...